TGF-beta-induced SMAD signaling and gene regulation: consequences for extracellular matrix remodeling and wound healing.

Members of the transforming growth factor-beta (TGF-beta) superfamily are pleiotropic cytokines that have the ability to regulate numerous cell functions, including proliferation, differentiation, apoptosis, epithelial-mesenchymal transition, and production of extracellular matrix, allowing them to play an important role during embryonic development and for maintenance of tissue homeostasis. Three TGF-beta isoforms have been identified in mammals. They propagate their signal via a signal transduction network involving receptor serine/threonine kinases at the cell surface and their substrates, the SMAD proteins. Upon phosphorylation and oligomerization, the latter move into the nucleus to regulate transcription of target genes. This review will summarize recent advances in the understanding of the mechanisms underlying SMAD modulation of extracellular matrix gene expression in the context of wound healing and tissue fibrosis.

[1]  S. Jimenez,et al.  Alterations in the regulation of expression of the αl(I) collagen gene (COL1A1) in systemic sclerosis (scleroderma) , 2000, Springer Seminars in Immunopathology.

[2]  A. Mauviel,et al.  Cyclic adenosine 3′,5′-monophosphate-elevating agents inhibit transforming growth factor-β-induced SMAD3/4-dependent transcription via a protein kinase A-dependent mechanism , 2003, Oncogene.

[3]  Y. Inagaki,et al.  Interferon-γ Interferes with Transforming Growth Factor-β Signaling through Direct Interaction of YB-1 with Smad3* , 2003, Journal of Biological Chemistry.

[4]  T. T. Nguyen,et al.  Synchronous Activation of ERK and Phosphatidylinositol 3-Kinase Pathways Is Required for Collagen and Extracellular Matrix Production in Keloids* , 2003, Journal of Biological Chemistry.

[5]  D. Abraham,et al.  Fibroblast-specific Expression of a Kinase-deficient Type II Transforming Growth Factor β (TGFβ) Receptor Leads to Paradoxical Activation of TGFβ Signaling Pathways with Fibrosis in Transgenic Mice* , 2003, Journal of Biological Chemistry.

[6]  S. Dooley,et al.  Smad7 prevents activation of hepatic stellate cells and liver fibrosis in rats. , 2003, Gastroenterology.

[7]  J. Varga,et al.  Expression and regulation of intracellular SMAD signaling in scleroderma skin fibroblasts. , 2003, Arthritis and rheumatism.

[8]  R. Morishita,et al.  Inhibition of renal fibrosis by gene transfer of inducible Smad7 using ultrasound-microbubble system in rat UUO model. , 2003, Journal of the American Society of Nephrology : JASN.

[9]  Y. Inagaki,et al.  Y-box-binding Protein YB-1 Mediates Transcriptional Repression of Human α2(I) Collagen Gene Expression by Interferon-γ* , 2003, The Journal of Biological Chemistry.

[10]  E. Wagner,et al.  A Central Role for the JNK Pathway in Mediating the Antagonistic Activity of Pro-inflammatory Cytokines against Transforming Growth Factor-β-driven SMAD3/4-specific Gene Expression* , 2003, The Journal of Biological Chemistry.

[11]  高河 慎介.  Sustained activation of fibroblast transforming growth factor-β/Smad signaling in a murine model of scleroderma , 2003 .

[12]  E. Wagner,et al.  Distinct involvement of the Jun‐N‐terminal kinase and NF‐κB pathways in the repression of the human COL1A2 gene by TNF‐α , 2002 .

[13]  J. Jaffrezou,et al.  p38 MAPK mediates the regulation of α1(I) procollagen mRNA levels by TNF‐α and TGF‐β in a cell line of rat hepatic stellate cells 1 , 2002 .

[14]  L. Wakefield,et al.  Lifetime exposure to a soluble TGF-beta antagonist protects mice against metastasis without adverse side effects. , 2002, The Journal of clinical investigation.

[15]  M. Goumans,et al.  Overexpression of Smad7 results in severe pathological alterations in multiple epithelial tissues , 2002, The EMBO journal.

[16]  F. Verrecchia,et al.  Control of connective tissue gene expression by TGFβ: Role of smad proteins in fibrosis , 2002, Current rheumatology reports.

[17]  D. Abraham,et al.  Connective tissue growth factor: A new and important player in the pathogenesis of fibrosis , 2002, Current rheumatology reports.

[18]  D. Shegogue,et al.  Role of p38 MAPK in transforming growth factor beta stimulation of collagen production by scleroderma and healthy dermal fibroblasts. , 2002, The Journal of investigative dermatology.

[19]  P. Goldschmidt-Clermont,et al.  Deficient Smad7 expression: A putative molecular defect in scleroderma , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[20]  F. Verrecchia,et al.  Transforming Growth Factor-β Signaling Through the Smad Pathway: Role in Extracellular Matrix Gene Expression and Regulation , 2002 .

[21]  M. Karin,et al.  c-Jun N-terminal kinase is required for metalloproteinase expression and joint destruction in inflammatory arthritis. , 2001, The Journal of clinical investigation.

[22]  A. Roberts,et al.  Smad3/AP-1 interactions control transcriptional responses to TGF-β in a promoter-specific manner , 2001, Oncogene.

[23]  F. Verrecchia,et al.  Identification of Novel TGF-β/Smad Gene Targets in Dermal Fibroblasts using a Combined cDNA Microarray/Promoter Transactivation Approach* , 2001, The Journal of Biological Chemistry.

[24]  Tomoki Chiba,et al.  Smurf1 Interacts with Transforming Growth Factor-β Type I Receptor through Smad7 and Induces Receptor Degradation* , 2001, The Journal of Biological Chemistry.

[25]  S. Sa,et al.  CTGF and SMADs, Maintenance of Scleroderma Phenotype Is Independent of SMAD Signaling* , 2001, The Journal of Biological Chemistry.

[26]  A. Ghosh,et al.  Antagonistic regulation of type I collagen gene expression by interferon-gamma and transforming growth factor-beta. Integration at the level of p300/CBP transcriptional coactivators. , 2001, The Journal of biological chemistry.

[27]  J. Uitto,et al.  Cytokine modulation of extracellular matrix gene expression: relevance to fibrotic skin diseases. , 2000, Journal of dermatological science.

[28]  J. Wrana,et al.  Smad7 binds to Smurf2 to form an E3 ubiquitin ligase that targets the TGF beta receptor for degradation. , 2000, Molecular cell.

[29]  A. Atfi,et al.  Tumor Necrosis Factor-α Inhibits Transforming Growth Factor-β /Smad Signaling in Human Dermal Fibroblasts via AP-1 Activation* , 2000, The Journal of Biological Chemistry.

[30]  A. Roberts,et al.  A novel smad nuclear interacting protein, SNIP1, suppresses p300-dependent TGF-beta signal transduction. , 2000, Genes & development.

[31]  L. Khachigian,et al.  Induction of Platelet-derived Growth Factor B-chain Expression by Transforming Growth Factor-β Involves Transactivation by Smads* , 2000, The Journal of Biological Chemistry.

[32]  J. Massagué,et al.  Transcriptional control by the TGF‐β/Smad signaling system , 2000 .

[33]  E. Bottinger,et al.  A mechanism of suppression of TGF–β/SMAD signaling by NF-κB/RelA , 2000, Genes & Development.

[34]  Xin-Hua Feng,et al.  Microtubule Binding to Smads May Regulate TGFβ Activity , 2000 .

[35]  R. Derynck,et al.  Smad2, Smad3 and Smad4 cooperate with Sp1 to induce p15(Ink4B) transcription in response to TGF-beta. , 2000, The EMBO journal.

[36]  S. Teitelbaum,et al.  Transforming growth factor-beta up-regulates the beta 5 integrin subunit expression via Sp1 and Smad signaling. , 2000, The Journal of biological chemistry.

[37]  C. Heldin,et al.  Specificity, diversity, and regulation in TGF‐β superfamily signaling , 1999 .

[38]  Yan Chen,et al.  Regulation of Smad7 Promoter by Direct Association with Smad3 and Smad4* , 1999, The Journal of Biological Chemistry.

[39]  R. Weinberg,et al.  SnoN and Ski protooncoproteins are rapidly degraded in response to transforming growth factor beta signaling. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[40]  E. Nishida,et al.  Involvement of the p38 Mitogen-activated Protein Kinase Pathway in Transforming Growth Factor-β-induced Gene Expression* , 1999, The Journal of Biological Chemistry.

[41]  Qiang Zhou,et al.  The Ski oncoprotein interacts with the Smad proteins to repress TGFbeta signaling. , 1999, Genes & development.

[42]  Anita B. Roberts,et al.  Mice lacking Smad3 show accelerated wound healing and an impaired local inflammatory response , 1999, Nature Cell Biology.

[43]  K. Miyazono,et al.  Transient gene transfer and expression of Smad7 prevents bleomycin-induced lung fibrosis in mice. , 1999, The Journal of clinical investigation.

[44]  J. Massagué,et al.  A Smad Transcriptional Corepressor , 1999, Cell.

[45]  S. Tashiro,et al.  ATF-2 Is a Common Nuclear Target of Smad and TAK1 Pathways in Transforming Growth Factor-β Signaling* , 1999, The Journal of Biological Chemistry.

[46]  P. Howe,et al.  TGF‐β induces fibronectin synthesis through a c‐Jun N‐terminal kinase‐dependent, Smad4‐independent pathway , 1999, The EMBO journal.

[47]  J. Massagué,et al.  Inhibition of transforming growth factor-β/SMAD signalling by the interferon-γ/STAT pathway , 1999, Nature.

[48]  Morgan Huse,et al.  Crystal Structure of the Cytoplasmic Domain of the Type I TGF β Receptor in Complex with FKBP12 , 1999, Cell.

[49]  E. Lai,et al.  FAST-2 Is a Mammalian Winged-Helix Protein Which Mediates Transforming Growth Factor β Signals , 1999, Molecular and Cellular Biology.

[50]  S. J. Chen,et al.  Stimulation of type I collagen transcription in human skin fibroblasts by TGF-beta: involvement of Smad 3. , 1999, The Journal of investigative dermatology.

[51]  Liliana Attisano,et al.  SARA, a FYVE Domain Protein that Recruits Smad2 to the TGFβ Receptor , 1998, Cell.

[52]  A. Roberts,et al.  SMAD3/4-dependent transcriptional activation of the human type VII collagen gene (COL7A1) promoter by transforming growth factor beta. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[53]  Xing Shen,et al.  TGF-beta-induced phosphorylation of Smad3 regulates its interaction with coactivator p300/CREB-binding protein. , 1998, Molecular biology of the cell.

[54]  J. Massagué,et al.  Physical and Functional Interaction of SMADs and p300/CBP* , 1998, The Journal of Biological Chemistry.

[55]  Yigong Shi,et al.  Crystal Structure of a Smad MH1 Domain Bound to DNA Insights on DNA Binding in TGF-β Signaling , 1998, Cell.

[56]  C. Heldin,et al.  The L45 loop in type I receptors for TGF‐β family members is a critical determinant in specifying Smad isoform activation , 1998, FEBS letters.

[57]  C. Heldin,et al.  Identification and Functional Characterization of a Smad Binding Element (SBE) in the JunB Promoter That Acts as a Transforming Growth Factor-β, Activin, and Bone Morphogenetic Protein-inducible Enhancer* , 1998, The Journal of Biological Chemistry.

[58]  J. D. Brown,et al.  CREB binding protein is a required coactivator for Smad-dependent, transforming growth factor beta transcriptional responses in endothelial cells. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[59]  T. Hunter,et al.  TGF-beta-stimulated cooperation of smad proteins with the coactivators CBP/p300. , 1998, Genes & development.

[60]  R. Derynck,et al.  The tumor suppressor Smad4/DPC4 and transcriptional adaptor CBP/p300 are coactivators for smad3 in TGF-beta-induced transcriptional activation. , 1998, Genes & development.

[61]  P. Hoodless,et al.  Smad2 and Smad3 positively and negatively regulate TGF beta-dependent transcription through the forkhead DNA-binding protein FAST2. , 1998, Molecular cell.

[62]  Denis Vivien,et al.  Direct binding of Smad3 and Smad4 to critical TGFβ‐inducible elements in the promoter of human plasminogen activator inhibitor‐type 1 gene , 1998, The EMBO journal.

[63]  A. Roberts,et al.  Smad-dependent Transcriptional Activation of Human Type VII Collagen Gene (COL7A1) Promoter by Transforming Growth Factor-β* , 1998, The Journal of Biological Chemistry.

[64]  J. Wrana,et al.  Mads and Smads in TGFβ signalling , 1998 .

[65]  J. Uitto,et al.  A proximal element within the human α2(I) collagen (COL1A2) promoter, distinct from the tumor necrosis factor-α response element, mediates transcriptional repression by interferon-γ , 1998 .

[66]  K. Kinzler,et al.  Human Smad3 and Smad4 are sequence-specific transcription activators. , 1998, Molecular cell.

[67]  J. Massagué,et al.  Smad6 inhibits BMP/Smad1 signaling by specifically competing with the Smad4 tumor suppressor. , 1998, Genes & development.

[68]  J. Massagué,et al.  TGF- SIGNAL TRANSDUCTION , 1998 .

[69]  C. Heldin,et al.  Identification of Smad7, a TGFβ-inducible antagonist of TGF-β signalling , 1997, Nature.

[70]  K. Miyazono,et al.  Smad6 inhibits signalling by the TGF-β superfamily , 1997, Nature.

[71]  Minoru Watanabe,et al.  Smad4 and FAST-1 in the assembly of activin-responsive factor , 1997, Nature.

[72]  J. Massagué,et al.  Mutations increasing autoinhibition inactivate tumour suppressors Smad2 and Smad4 , 1997, Nature.

[73]  J. Massagué,et al.  The TGF-beta family mediator Smad1 is phosphorylated directly and activated functionally by the BMP receptor kinase. , 1997, Genes & development.

[74]  R. Derynck,et al.  Expression of a dominant-negative type II transforming growth factor β (TGF-β) receptor in the epidermis of transgenic mice blocks TGF-β-mediated growth inhibition , 1997 .

[75]  R. Davis,et al.  Evidence for a Role of Rho-like GTPases and Stress-activated Protein Kinase/c-Jun N-terminal Kinase (SAPK/JNK) in Transforming Growth Factor β-mediated Signaling* , 1997, The Journal of Biological Chemistry.

[76]  S. O'Kane,et al.  Transforming growth factor βs and wound healing , 1997 .

[77]  G. Boivin,et al.  TGF β 2 knockout mice have multiple developmental defects that are non-overlapping with other TGF β knockout phenotypes , 1997 .

[78]  P. Hoodless,et al.  MADR2 Is a Substrate of the TGFβ Receptor and Its Phosphorylation Is Required for Nuclear Accumulation and Signaling , 1996, Cell.

[79]  H. Link,et al.  Transforming growth factor-beta 1 (TGF-beta1)-mediated inhibition of glial cell proliferation and down-regulation of intercellular adhesion molecule-1 (ICAM-1) are interrupted by interferon-gamma (IFN-gamma). , 1996, Clinical and experimental immunology.

[80]  M. Ferguson,et al.  Transforming growth factor–β3 is required for secondary palate fusion , 1995, Nature Genetics.

[81]  D. Foreman,et al.  Neutralisation of TGF-β 1 and TGF-β 2 or exogenous addition of TGF-β 3 to cutaneous rat wounds reduces scarring , 1995 .

[82]  G. Proetzel,et al.  Targeted disruption of the mouse transforming growth factor-β1 gene results in multifocal inflammatory disease , 1992, Nature.

[83]  D. Rouillard,et al.  IFN-gamma and transforming growth factor-beta 1 differently regulate fibronectin and laminin receptors of human differentiating monocytic cells. , 1992, Journal of immunology.

[84]  R. Weinberg,et al.  Expression cloning of the TGF-β type II receptor, a functional transmembrane serine/threonine kinase , 1992, Cell.

[85]  M. Sporn,et al.  The Transforming Growth Factor‐Betas: Past, Present, and Future , 1990, Annals of the New York Academy of Sciences.